|
US pulmonologists view refractory asthma patient treatment with biosimilar …
The Pharma Letter US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent of their severe, refractory asthma patients are treated with Genentech and Novartis' Xolair (omalizumab), the only approved drug that serves this … |
View full post on asthma – Google News